Diasorin’s Post

🌟 Take a glimpse into the groundbreaking work happening at IPATH, a hub of innovation and excellence within the field of medicine. 💊🔬 Our team is dedicated to pioneering research, driving advancements, and pushing the boundaries of what's possible in the fight against #antimicrobialresistance. 🦠💪 Curious to learn more about our cutting-edge projects, collaborations, and the transformative impact of phage therapies? 💡 Dive into the details on our website. 🚀 Here's why you should explore it!: 1️⃣ In-Depth Insights: Uncover the science behind phage applications and therapeutics with detailed information on our ongoing research initiatives. 2️⃣ Meet the Experts: Get to know the brilliant minds behind the groundbreaking discoveries, their expertise, and the passion driving our mission. 3️⃣ Impactful Stories: Discover real-life stories showcasing the positive impact of phage therapies on patients' lives. Join us on this journey of discovery, innovation, and healing! 🌍💙 Your support and interest make a difference. Feel free to like, share, and spread the word! Together, let's make strides in transforming healthcare and shaping a healthier future. #PhageTherapeutics #InnovationInMedicine #HealthcareRevolution #ResearchExcellence

Explore the iCMLf Knowledge Centre! Our interactive online resource is designed to provide you with cutting-edge educational content on CML patient management, molecular monitoring options, and practical considerations for BCR-ABL1 testing. Dive into the “Management of Advanced Phase CML” module, chaired by Professor Mhairi Copland (UK) and Dr. Virginia Abello Polo (Colombia). This module covers essential topics for the practical management of advanced phase CML. Discover more about: 1. Advanced Phase Disease: Definitions and the Role of Allograft 2. Blast Phase: Lymphoid 3. Blast Phase: Myeloid 4. Perspectives from Emerging Regions Visit now to enhance your knowledge: https://buff.ly/3UxTGSV #CML #ChronicMyeloidLeukemia #MedicalEducation #iCMLf #KnowledgeCentre

🚨 ICYMI our co-founder, Dr Tim Jobson, recently penned an insightful article published by pharmaphorum all about the increasing challenges that face sponsors running clinical trials for Metabolic Associated Steatohepatitis (MASH). With over 2 million deaths from liver disease last year, MASH research faces hurdles like limited participant pools and a lack of experienced trial sites. However, innovative tools, like our hepatoSIGHT, could enhance early detection and streamline recruitment. Read the full article now 👉  https://lnkd.in/eHyRuUtb #ClinicalTrials #MASH #NASH #LiverDisease

🎉 New Publication Alert from ASPIRE PMRIAD! 🎉 We're excited to share our team's groundbreaking findings on HHT1, published in Traffic (https://lnkd.in/dN6tA736). The study sheds light on how specific endoglin mutants retained in the endoplasmic reticulum can worsen the condition of hereditary hemorrhagic telangiectasia type 1 by negatively impacting the wild-type allele. 🔬 Key Discoveries: - Identification of how specific endoglin mutants impair the normal function of the wild-type protein. - Insights into the disease mechanism of HHT1, offering new avenues for therapeutic strategies. These findings not only deepen the understanding of HHT1 but also set the stage for future research in precision medicine. This milestone underscores our institute's commitment to advancing knowledge and improving healthcare outcomes. Read the full article here: https://lnkd.in/dt_NPgsp #ASPIREPMRIAD #HHT1Research #MedicalInnovation #TrafficJournal #precisionmedicine

📢 Exciting news! The #IRDiRC paper "Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community" is now on Frontiers in Medicine (open access)! Dive into the latest insights from the IRDiRC Task Force on lessons learned and emerging trends in drug repurposing.#RareDiseases #DrugRepurposing #OpenAccess  🔗https://lnkd.in/dKQp6bDF

📢 Exciting news! The #IRDiRC paper "Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community" is now on Frontiers in Medicine (open access)! Dive into the latest insights from the IRDiRC Task Force on lessons learned and emerging trends in drug repurposing. 🔗 https://bit.ly/48Ejj9a #RareDiseases #DrugRepurposing #OpenAccess 

Last week, we’ve reached the next important milestone in our Phase II clinical trial with Rovunaptabin: The last participant has been enrolled in the study. We are very grateful to be working together with such competent clinical centres who have made it possible to reach this milestone on time.   The upcoming months will be pivotal as our team analyses and evaluates the results that could redefine the treatment for Long COVID patients – and millions more affected by diseases associated with functional autoantibodies (fAABs). The promise of our platform technology BC 007 is not just to alleviate symptoms but to address the underlying cause of the disease by targeting and eliminating fAABs. Initial results of the Phase II trial in Long COVID patients are anticipated in Q4.   Stay tuned as we finalise the study, eager to uncover the data that will guide our way forward.   #LongCOVID #ClinicalTrials #Biotech #BC007

✨ Day 2 Recap (It's late, but there is so much greatness going on!) APHL - Association of Public Health Laboratories is doing a great job of changing up session types, with a balance between providing multiple lectures at the same time and then bringing everyone back together for single sessions. On Day 2, I focused on Next Generation Sequencing (NGS). NGS can be utilized in many ways in the Public Health Labs (PHLs), for instance in wastewater surveillance, isolate relatedness for outbreak investigations, and antimicrobial resistance (AMR) testing. Wastewater surveillance coupled with NGS gained traction post-COVID and many labs are evaluating the technique to assess what pathogens (and resistance genes for some organisms) can be detected in their vicinity. These were primarily limited to respiratory and stool pathogens as well as Candida auris. Studies are focusing on: 💦 Sampling methods – What locations to collect, what to test (water vs. biofilm near water line), how much sample to collect, etc. ⚗ What methods/assays/analytics to employ 📌 Relevancy of results Speaking of waste… 💩 testing has posed a challenge to PHLs when labs under their purview move towards CIDTs – Culture Independent Diagnostic Tests. This has led to another application of NGS in the PHL space – confirmation of CIDT results. While there are many benefits to NGS, there are also downsides (it’s hard to have a perfect test!) one of which being validations for clinical reporting. We heard insights from the CDC, FDA, and Wadsworth about some of these challenges. Did I mention there were also puppies here? #PublicHealth #NGS #Wastewater #AMR

The latest #IRDiRC paper "Drug Repurposing for Rare: Progress and Opportunities for the Rare Disease Community" is now available on Frontiers in Medicine (open access)! Dive into the latest insights from the IRDiRC Task Force on lessons learned and emerging trends in drug repurposing. #RareDiseases #DrugRepurposing #OpenAccess  🔗https://lnkd.in/eH8rZC34